Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis-Reference-Cited by-同舟云学术

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis

Published:2018-04-28 Issue:7 Volume:93 Page:E159-E161
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Caocci Giovanni¹^ORCID,Mulas Olga²,Annunziata Mario³,Luciano Luigiana⁴,Bonifacio Massimiliano⁵,Orlandi Ester Maria⁶,Pregno Patrizia⁷,Galimberti Sara⁸^ORCID,Russo Rossi Antonella⁹,Abruzzese Elisabetta¹⁰,Iurlo Alessandra¹¹^ORCID,Martino Bruno¹²,Sgherza Nicola¹³,Binotto Gianni¹⁴,Castagnetti Fausto¹⁵,Gozzini Antonella¹⁶,Fozza Claudio¹⁷^ORCID,Bocchia Monica¹⁸^ORCID,Sicuranza Anna¹⁸,Stagno Fabio¹⁹,Efficace Fabio²⁰^ORCID,Usala Emilio²,De Gregorio Fiorenza⁴,Scaffidi Luigi⁵,Elena Chiara⁶,Pirillo Francesca⁷,Baratè Claudia⁸,Trawinska Malgorzata Monika¹⁰,Cattaneo Daniele¹¹,Labate Claudia¹²,Gugliotta Gabriele¹⁵,Molica Matteo²¹^ORCID,Specchia Giorgina⁹,La Nasa Giorgio¹,Foà Robin²¹,Breccia Massimo²¹^ORCID

Affiliation:

1. Department of Medical Sciences and Public Health; University of Cagliari; Cagliari

2. Businco Hospital; Hematology and Transplant Center; Cagliari

3. Hematology Unit, Cardarelli Hospital; Naples

4. Hematology Unit “Federico II” University of Naples; Naples

5. Department of Medicine; Section of Hematology, University of Verona; Verona

6. Hematology Unit, “Fondazione IRCCS Policlinico S. Matteo” University Hospital; Pavia

7. Hematology Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza; Torino

8. Department of Clinical and Experimental Medicine; Section of Hematology, University of Pisa; Pisa

9. Hematology and Transplants Unit, University of Bari; Bari

10. Hematology Unit, Sant'Eugenio Hospital Tor Vergata University; Rome

11. Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milano

12. Hematology Unit, Azienda Ospedaliera “Bianchi-Melacrino-Morelli”; Reggio Calabria

13. Casa Sollievo della Sofferenza Hospital; Hematology and Transplant Center; San Giovanni Rotondo

14. Hematology Unit, University of Padova; Padua

15. Department of Experimental, Diagnostic and Specialty Medicine; S. Orsola-Malpighi Hospital, University of Bologna; Bologna

16. Hematology Unit, AOU Careggi, University of Florence; Florence

17. Department of Clinical and Experimental Medicine; University of Sassari; Sassari

18. Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena; Siena

19. Hematology Unit, Ferrarotto Hospital; Catania

20. Italian Group for Adult Hematologic Diseases (GIMEMA); Data Center and Health Outcomes Research Unit; Rome

21. Division of Hematology, Department of Cellular Biotechnologies and Hematology; Policlinico Umberto I, Sapienza University; Rome Italy

Publisher

Wiley

Subject

Hematology

Reference7 articles.

1. Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based oncology practices in the United States;Coutinho;Clin Lymphoma Myeloma Leuk.,2017

2. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study;Dahlén;Ann Intern Med.,2016

3. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance;Aghel;VHRM.,2017

4. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment;Breccia;Ann Hematol.,2015

5. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients;Castagnetti;Haematologica.,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies;Current Treatment Options in Oncology;2023-12

2. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib;Annals of Hematology;2023-11-28

3. Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation;Scientific Reports;2023-07-21

4. Vascular complications in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors;Journal of the Korean Medical Association;2023-04-10

5. Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance;International Journal of Molecular Sciences;2022-10-14